Objective. Lipid abnormalities contribute to the increased risk of premature atherosclerosis in patients with SLE. This study was undertaken to investigate changes in lipid profile after B-cell depletion therapy (BCDT) in patients with active SLE who had failed standard immunosuppressive therapy.
Introduction
Cardiovascular disease is increased in patients with SLE compared with the general population. Coronary artery disease (CAD) risk is 50 times greater in women with SLE aged 35-44 years [1] . This increase is attributed to a variety of traditional and non-traditional risk factors for atherosclerosis [2] [3] [4] . Lipid abnormalities are likely to be one of the contributing causes. Different patterns of dyslipoproteinaemia have been identified in patients with SLE [5] [6] [7] [8] . One factor is attributable to the disease itself and consists of low levels of high-density lipoprotein (HDL) cholesterol with elevated very low-density lipoprotein (VLDL) cholesterol and triglycerides (TGs). These lipid profile abnormalities are aggravated by disease activity [7, 8] . The other factor is attributable, in part, to corticosteroid therapy and consists of increased total, and VLDL cholesterols and TGs.
In open-label studies, B-cell depletion therapy (BCDT) based on rituximab (a monoclonal antibody that selectively targets CD20 + B cells) appears to be an effective way of treating lupus patients who have failed to respond to conventional immunosuppressive drugs [9] . Few published studies have described longitudinal data on lipid levels in patients with SLE. Furthermore, there are no reports on the effect of immunosuppressive treatments on the lipid profile in lupus patients with refractory disease.
Given the paucity of data in the current literature, the aim of our provisional study was to investigate whether treatment with rituximab, a drug with no known direct effects on lipid metabolism, was followed by improvements in the lipid profile in patients with active SLE who had failed standard immunosuppressive therapy.
Patients and methods

Study patients
The University College London Hospital (UCLH) cohort consists of 535 patients diagnosed with lupus and prospectively followed between January 1978 and June 2009. Since June 2000, 74 patients attending the Lupus Clinic from the UCLH have undergone treatment with BCDT after failing to respond to conventional immunosuppressive agents. We analysed all these patients and selected those who fulfilled the following inclusion criteria for the study: (i) at least four of the 1997 ACR revised criteria for the classification of SLE [10] ; (ii) had failed to respond to at least two conventional immunosuppressive agents (MTX, AZA, mycophenolate mofetil and cyclophosphamide) requiring BCDT; and (iii) availability of laboratory data on lipid status performed <3 months before BCDT and 12 months later. Exclusion criterion was the starting or increase in dose of lipid-lowering treatment during the study period or 6 months before.
All patients were offered BCDT on the basis of clinical need (and not for the purpose of research) and gave informed consent to receive a combination protocol (1 g of rituximab and 750 mg of cyclophosphamide with 100 or 250 mg of intravenous methylprednisolone) given 2 weeks apart. Immunosuppressive drugs were stopped before the commencement of BCDT in order to reduce the risk of septic complications.
We analysed the changes in the lipid profile in a control group of 26 age-and sex-matched lupus patients who had annual determinations of serum lipid profile and had not been treated with BCDT. This study did not involve any research procedures or tests outside the routine management of patients, and all patients were managed according to the same criteria. Approval of a research ethics committee was therefore not sought.
Data collection
Data on age at the time of the study entry, mean duration of disease, sex, ethnicity, system involvement requiring BCDT, duration of B-cell depletion, concomitant treatment, dose of steroids during the study time, cigarette smoking status and blood pressure were collected. Lupus activity was assessed at each visit using the BILAG activity index [11] , anti-double-stranded (ds) DNA antibody levels by ELISA (Shield Diagnostics, Dundee, UK) and serum C3 levels determined by laser nephelometry. Patients were considered to have achieved B-cell depletion if absolute CD19 counts were <0.005 Â 10 9 / litre after 1 week. These clinical and laboratory data were collected and entered into a specific computer program BLIPS (British Lupus Integrated Prospective System) [12] .
Lipid determinations
All blood samples (non-fasting) were collected in the morning at the time of attending the Lupus Clinic. Lipid measurements were performed before (<3 months) and after (1 year ± 3 months) receiving rituximab. The levels of total, HDL and low-density lipoprotein (LDL) cholesterols and TGs were determined using a Roche Modular Analyzer (normal ranges: 2.5-5.0, 1.2-1.7, 0-3.5 and 0.4-2.3 mmol/l, respectively).
Statistical analysis
Results are presented as the mean (S.D.) and percentages. The numeric BILAG score (using an A = 9, B = 3, C = 1, D/E = 0 notation), C3, anti-dsDNA antibodies, levels of total, HDL and LDL cholesterols, TGs and the total cholesterol/HDL ratio (the atherogenic index) were compared at the time before BCDT and 1 year after using the Wilcoxon signed-rank test. To investigate the association between the changes in lipid levels and changes in lupus activity over the study period, Spearman's rank correlation coefficient was calculated. P < 0.05 was considered statistically significant. All analyses were performed using the statistical software SPSS version 15.0 (SPSS, Chicago, IL, USA).
Results
Twelve patients were included in our study. The individual data for all of them are shown in Table 1 . Their baseline clinical characteristics are given in Table 2 . The average duration of B-cell depletion was 6.4 (5.0) months (range 0-18 months). One patient did not achieve B-cell depletion, but showed reduction in the BILAG score from 15 to 5 and in the atherogenic index from 8.3 to 4.4. The control group consisted of 26 women [mean age (S.D.) 40.2 (11.7) years]. The baseline BILAG score in the control group was significantly lower than in the study group [4.0 (2.7) and 11.0 (3.6), respectively; P < 0.001].
Baseline lipid profile
Three and two patients of the study group had values of total and LDL cholesterols above the normal range at baseline, respectively. Five of the 12 patients had levels of HDL cholesterol at baseline under the normal range. Three of the 12 patients had levels of TGs at baseline above the normal range.
Changes in the lipid levels 1 year after BCDT HDL cholesterol levels increased by 14.3% in the study group after BCDT (P = 0.04). Nine patients recorded an increase in HDL cholesterol levels 1 year after treatment. The values of the atherogenic index decreased by 26.3% after treatment with BCDT (P = 0.02). Nine patients recorded a reduction in this index after treatment. The levels of TGs decreased significantly by 38.1% 1 year after BCDT compared with baseline (P = 0.04). Eight patients recorded a reduction in the levels of TGs during the study period. The levels of total and LDL cholesterols were lower after BCDT than at baseline (P = NS for both comparisons). There were no significant differences in the changes in lipid levels between patients who were being treated with a stable dose of statins and those without statins. There were no significant differences in the changes in lipid levels between patients depending on which system necessitated BCDT either. In the patients of the control group, there were no significant differences in any of the lipid determinations over a 1-year period.
We observed some significant differences in the changes in the lipid profile over 1 year between the patients in the study group and those in the control group. HDL cholesterol levels increased in the study group and remained stable in the control group [0.2 (0.2) and À0.08 (0.3), respectively; P = 0.01]. The values of the atherogenic index decreased in the study group and increased in the control group [À1.1 (1.4) and +0.1 (0.6), respectively; P = 0.001]. The levels of TGs decreased in the study group and remained stable in the control group [À0.7 (1.0) and À0.06 (0.4), respectively; P = 0.005]. We did not observe significant differences in the levels of total and LDL cholesterols between the two groups.
Changes in lupus activity after BCDT
The variations in the activity of the disease over the year of study are shown in Table 2 . The mean doses of prednisolone at the time of B-cell depletion and 12 months later were 11.2 (5.2) mg/day (range 0-20 mg/day) and 7.4 (3.2) mg/day (range 0-11.25 mg/day), respectively (P = 0.01). The average cumulative and daily doses of prednisolone or equivalent during the study time were 3445 (1648) mg and 9.9 (4.8) mg/day, respectively. Association between lipid levels and measurement of lupus activity
We found statistically significant correlations between activity of the disease at baseline measured by antidsDNA antibody titre and some baseline lipid determinations such as values of TGs and atherogenic index (r = 0.60, P = 0.03 and r = 0.56, P = 0.05, respectively). We also found a positive association between the reduction in lupus activity and the improvement in some lipid determinations. Thus, the decrease in BILAG score after BCDT correlated significantly with the increase in HDL cholesterol levels over the study period (r = 0.69, P = 0.01). The reduction in lupus activity after BCDT measured by anti-dsDNA antibody titres associated significantly with the reduction in the levels of total cholesterol and TGs over the study period. Figures 1 and 2 show these associations. We did not find any correlation between the 
Discussion
In this provisional study, we report that low levels of HDL cholesterol and increased triglyceridaemia (lupus dyslipoproteinaemia) in patients who failed standard immunosuppressive treatment improved after BCDT. Ilowite et al. [5] identified two different patterns of dyslipoproteinaemia in SLE. One is attributable to active disease and consists of reduced HDL levels and apoprotein A-1 with elevated levels of VLDL cholesterol and TGs. The other is mainly attributable to corticosteroid therapy
FIG. 1
Correlation between the reduction in lupus activity measured by anti-dsDNA antibody titres and the reduction in the levels of total cholesterol after BCDT. The straight line is the best-fit line. The curves delimit the 95% CI for the mean. and consists of increased total and VLDL cholesterols and TGs. Ettinger et al. [6] described that lupus patients treated with prednisone have higher TGs and total and LDL cholesterol levels than those not treated with prednisone. Borba and Bonfá [7] observed high levels of VLDL cholesterol and TG, and low levels of HDL cholesterol in inactive SLE compared with controls (P < 0.05). Active disease aggravates this abnormality in the lipid profile by inducing a more striking increase in VLDL cholesterol and TG levels and a more significant decrease in HDL cholesterol. Svenungsson et al. [8] also demonstrated a significant correlation of dyslipoproteinaemia with high TG/low HDL cholesterol levels and the activity of lupus measured by SLE disease activity measure (SLAM). Since HDL cholesterol levels are inversely associated with CAD and hypertriglyceridaemia is a highly significant independent risk factor for CAD in women, lupus itself appears to induce the presence of an atherogenic lipid profile [13, 14] .
We have shown that BCDT utilizing rituximab and cyclophosphamide is followed by an increase in HDL cholesterol and a fall in the total cholesterol/HDL ratio and TG levels in the majority of the patients. In our control group of age-and sex-matched lupus patients with lower baseline activity, we did not observe any significant change in any of the lipid determinations over a 1-year period. It is possible, though unlikely, that the changes in lipid levels in some study patients may have arisen due to change in diet or use of a lower dose of corticosteroids. During this period, we did not give dietary advice to any of these patients and none were receiving advice on lowcholesterol diets elsewhere (to our knowledge). With regard to the dose of corticosteroids, BCDT was administered at the time of severe flares of activity of the disease, also requiring a higher dose of corticosteroids. Although it has been demonstrated that prednisone treatment is associated with raised levels of TG in lupus patients, we found a significant reduction in the levels of TG after BCDT [15] . Although the mean dose of prednisolone at the time of BCDT was significantly higher than that 12 months later, since all the patients remained on corticosteroids at a mean dose of 9.9 mg/day throughout the period of follow-up, it is unlikely that the improvement in lipids was due to the reduction in steroid dose. Furthermore, we found that both the mean cumulative and the mean daily doses of corticosteroids that our patients received during the time of this study [3446 (1649) and 9.9 (4.8), respectively] were higher than those received during a similar period before the administration of BCDT [3019 (1964) and 8.7 (6.3), respectively; P = NS for both comparisons]. Since BCDT acts positively on known risk factors for premature atherosclerosis such as HDL cholesterol, the total cholesterol/HDL ratio and TG levels, BCDT with rituximab and cyclophosphamide may lead to a reduction in the development of this late complication of lupus.
The improvement in the lipid abnormalities that our study showed after BCDT coincided with decreased disease activity as measured by the BILAG index and a fall   FIG. 2 Correlation between the reduction in lupus activity measured by anti-dsDNA antibody titres and the reduction in the levels of TGs after B-cell depletion therapy. The straight line is the best-fit line. The curves delimit the 95% CI for the mean.
www.rheumatology.oxfordjournals.org in the anti-dsDNA antibody levels. In several open-label studies, BCDT has been demonstrated to be a safe and effective therapy for patients with lupus [9] . Since rituximab has no known direct effect on lipid metabolism, it seems likely that the positive effect of BCDT on the lipid profile of our patients is indirectly mediated through a reduction in the inflammatory activity of the disease. This is a small provisional retrospective study looking for possible 'signals' of improvement in lipid profile achieved by rituximab and cyclophosphamide after treatment with BCDT. However, our baseline results are concordant with the literature and, unlike previous studies, our study reports longitudinal data on lipid levels over time.
In conclusion, as lipid abnormalities are frequently present in SLE patients, early recognition and implementation of a lipid-lowering strategy are strongly advised. Control of SLE appears to improve the levels of these lipids whose role in the development of premature atherosclerosis has been demonstrated. BCDT achieved by rituximab and cyclophosphamide in patients with refractory SLE was associated with a significant long-term improvement in lipid profile that correlated with decreasing activity of the disease. Further studies with larger populations are needed to determine whether these changes contribute to a significantly lower incidence of cardiovascular events.
Rheumatology key messages
. BCDT may have a positive effect on the lipid profile of lupus patients. . Larger prospective studies should evaluate if this favourable effect contributes to a lower incidence of cardiovascular events.
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